Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
Journal of medical economics | 2016-12-01 | PMID 27348464
Virabhak Suchin, Yasui Kikuo, Yamazaki Kiyotaka and 5 more
